National Reference Laboratory, Abu Dhabi, United Arab Emirates.
Pathology & Laboratory Medicine Institute (PLMI), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Front Immunol. 2023 Sep 1;14:1230974. doi: 10.3389/fimmu.2023.1230974. eCollection 2023.
There is substantial immunological evidence that vaccination following natural infection increases protection. We compare the humoral immune response developed in initially seropositive individuals (naturally infected) to humoral hybrid immune response (developed after infection and vaccination) in the same population group after one year.
The study included 197 male individuals who were naturally infected with SARS-CoV-2 and then vaccinated with SARS-CoV-2 vaccine. Trimeric spike, nucleocapsid, and ACE2-RBD blocking antibodies for SARS-CoV-2 were measured. Nasal swabs were collected for SARS-CoV-2 PCR testing. Information on vaccination against SARS-CoV-2 and PCR verified infection was retrieved from official databases (Abu Dhabi Health Data Services- SP LLC. ("Malaffi"), including number of vaccine doses received, date of vaccination, and type of the received vaccine.
All the study population were tested PCR-Negative at the time of sample collection. Our results showed that there was a significant rise in the mean (SD) and median (IQR) titers of trimeric spike, nucleocapsid and ACE2-RBD blocking antibodies in the post-vaccination stage. The mean (± SD) and median (IQR) concentration of the anti-S antibody rose by 3.3-fold (+230% ± 197% SD) and 2.8-fold (+185%, 220-390%, p<0.001), respectively. There was an observed positive dose-response relationship between number of the received vaccine doses and having higher proportion of study participants with higher than median concentration in the difference between the measured anti-S and ACE2-RBD blocking antibodies in the post-vaccination compared to pre-vaccination.
Our study demonstrates that COVID-19 vaccination post natural infection elicits a robust immunological response with an impressive rise of SARS-CoV-2 antibodies, especially the ACE2-RBD blocking antibodies.
有大量免疫学证据表明,自然感染后接种疫苗可增强保护作用。我们比较了同一人群中最初血清阳性个体(自然感染)和同一人群中感染后再接种疫苗后的混合免疫应答(混合免疫应答)在一年后的体液免疫应答。
该研究纳入了 197 名男性个体,他们曾自然感染 SARS-CoV-2,然后接种了 SARS-CoV-2 疫苗。测量了针对 SARS-CoV-2 的三聚体刺突、核衣壳和 ACE2-RBD 阻断抗体。采集鼻拭子进行 SARS-CoV-2 PCR 检测。从阿布扎比健康数据服务-SP 有限责任公司("Malaffi")等官方数据库中检索有关 SARS-CoV-2 疫苗接种和 PCR 证实感染的信息,包括接种疫苗的次数、接种日期和接种疫苗的类型。
在采集样本时,所有研究人群的 PCR 检测均为阴性。我们的结果表明,在接种疫苗后阶段,三聚体刺突、核衣壳和 ACE2-RBD 阻断抗体的平均(SD)和中位数(IQR)滴度均显著升高。抗-S 抗体的平均(± SD)和中位数(IQR)浓度分别升高了 3.3 倍(+230%±197% SD)和 2.8 倍(+185%,220-390%,p<0.001)。在接种疫苗后与接种疫苗前相比,测量的抗-S 抗体与 ACE2-RBD 阻断抗体之间的差异中,高于中位数浓度的研究参与者比例与所接种疫苗剂量之间存在观察到的正剂量反应关系。
我们的研究表明,COVID-19 自然感染后接种疫苗可引发强大的免疫反应,SARS-CoV-2 抗体,特别是 ACE2-RBD 阻断抗体显著升高。